PeproMene Bio Inc: Valuation, Funding & Investors
PeproMene Bio Inc is a biotechnology company focused on developing targeted immunotherapies for cancer and autoimmune diseases. The company is advancing its BAFF-R CAR T cell therapy, PMB-CT01, specifically for patients with relapsed or refractory follicular lymphoma. PeproMene Bio aims to address unmet medical needs in the treatment of B-cell Non-Hodgkin Lymphoma through innovative cellular therapies.
Leadership & Board
- Current Number of Employees
- 10
- Current LinkedIn Followers
- 702
Latest Estimated Valuation
- Total Amount Raised
- $11M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $11M
- Latest Funding Round
- Investment
Employee Trend
PeproMene Bio Inc had 10 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
PeproMene Bio Inc had 702 followers as of November 9, 2026. The number of followers increased by 2 (0.29%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Investment | $11.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Institute for Follicular Lymphoma Innovation | Investment |
Similar Companies
A snapshot of private companies similar to PeproMene Bio Inc, helping you discover and navigate related company profiles.
